In the BioHarmony Drug Report Database
Efmoroctocog alfa
Eloctate, Elocta (efmoroctocog alfa) is a fusion protein pharmaceutical. Efmoroctocog alfa was first approved as Eloctate on 2015-11-18. It has been approved in Europe to treat hemophilia a.
Trade Name
|
Elocta |
|---|---|
Common Name
|
efmoroctocog alfa |
ChEMBL ID
|
CHEMBL4297945 |
Indication
|
hemophilia a |
Drug Class
|
Fc fusion protein |
Image (chem structure or protein)
